相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis
Xiuli Xie et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials
Sanjay Chabra et al.
ADVANCES IN THERAPY (2022)
Latest combination therapies in psoriasis: Narrative review of the literature
Federico Diotallevi et al.
DERMATOLOGIC THERAPY (2022)
Managing pediatric psoriasis: update on treatments and challenges-a review
A. A. Hebert et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Update on the Management of Pediatric Psoriasis: An Italian Consensus
Ketty Peris et al.
DERMATOLOGY AND THERAPY (2022)
Metabolic Comorbidities and Cardiovascular Disease in Pediatric Psoriasis: A Narrative Review
Andrea Marani et al.
HEALTHCARE (2022)
Novel Therapeutic Approaches and Targets for Treatment of Psoriasis
Giulia Radi et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2021)
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial
C. Bodemer et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know
F. Diotallevi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches
Anna Campanati et al.
BIOMEDICINES (2021)
Pediatric Psoriasis: From New Insights into Pathogenesis to Updates on Treatment
Hye One Kim et al.
BIOMEDICINES (2021)
Safety and Efficacy of Vaccines during COVID-19 Pandemic in Patients Treated with Biological Drugs in a Dermatological Setting
Oriana Simonetti et al.
HEALTHCARE (2021)
Plasma oxidation status and antioxidant capacity in psoriatic children
Tiziana Bacchetti et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2020)
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Efficacy and safety of ixekizumab in a phaseIII, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)
A. S. Paller et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study
S. Philipp et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Safety update of etanercept treatment for moderate to severe plaque psoriasis
Anna Campanati et al.
EXPERT OPINION ON DRUG SAFETY (2020)
A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted drugs in the treatment of moderate to severe psoriasis
Jianzhen Shi et al.
DERMATOLOGIC THERAPY (2020)
How can I take care of you? The dermatologist meets patients' needs during the COVID-19 pandemic
Giulia Radi et al.
DERMATOLOGIC THERAPY (2020)
Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis
Kerasia-Maria Plachouri et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation
Vito D. Lernia et al.
DERMATOLOGIC THERAPY (2019)
Koebner phenomenon leading to the formation of new psoriatic lesions: evidences and mechanisms
Yong-Zhi Ji et al.
BIOSCIENCE REPORTS (2019)
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
Heejin Lim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Pediatric psoriasis: Evolving perspectives
Lawrence F. Eichenfield et al.
PEDIATRIC DERMATOLOGY (2018)
Association of Psoriasis With Comorbidity Development in Children With Psoriasis
Megha M. Tollefson et al.
JAMA DERMATOLOGY (2018)
Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis
Kelly M. Cordoro et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial
Kim Papp et al.
LANCET (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety of Systemic Agents for the Treatment of Pediatric Psoriasis
Inge M. G. J. Bronckers et al.
JAMA DERMATOLOGY (2017)
Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
George E. Fragoulis et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis
D. Mermin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Characterization of Th17 and FoxP3+ Treg Cells in Paediatric Psoriasis Patients
L. Zhang et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2016)
Psoriasis in children
Roxanne Pinson et al.
PSORIASIS-TARGETS AND THERAPY (2016)
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
Ian Landells et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Childhood Generalized Pustular Psoriasis: Longtime Remission With Combined Infliximab and Methotrexate Treatment
Andrea Skrabl-Baumgartner et al.
PEDIATRIC DERMATOLOGY (2015)
Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities
I. M. G. J. Bronckers et al.
PEDIATRIC DRUGS (2015)
Systemic Treatments for Severe Pediatric Psoriasis A Practical Approach
Ann L. Marqueling et al.
DERMATOLOGIC CLINICS (2013)
Infliximab-Associated Psoriasis in Children With Crohn's Disease May Require Withdrawal of Anti-Tumor Necrosis Factor Therapy
Tangra Broge et al.
INFLAMMATORY BOWEL DISEASES (2013)
Clinical Manifestations of Pediatric Psoriasis: Results of a Multicenter Study in the United States
Katherine Mercy et al.
PEDIATRIC DERMATOLOGY (2013)
Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial
Richard G. Langley et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Long-term etanercept in pediatric patients with plaque psoriasis
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
Mark Lebwohl et al.
Therapeutics and Clinical Risk Management (2010)
VEGF, survivin and NOS overexpression in psoriatic skin: Critical role of nitric oxide synthases
Oriana Simonetti et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2009)
Psoriasis: epidemiology, clinical features, and quality of life
RGB Langley et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
An update on the genetics of psoriasis
F Capon et al.
DERMATOLOGIC CLINICS (2004)
Successful treatment of pediatric psoriasis with infliximab
MA Menter et al.
PEDIATRIC DERMATOLOGY (2004)
Childhood psoriasis: A clinical review of 1262 cases
A Morris et al.
PEDIATRIC DERMATOLOGY (2001)
分享论文
